Research on Treatments for Alzheimer’s Disease Based on Its Pathological Mechanisms Recieves Award for Science and Technology (Research Category) Source Cluster: JCN Newswire Source Node: 1966335Time Stamp: Apr 17, 2024
Eisai Completes Submission of LEQEMBI (lecanemab-irmb) Supplemental Biologics License Application for IV Maintenance Dosing for the Treatment of Early Alzheimer’s Disease to the U.S. FDA Source Cluster: JCN Newswire Source Node: 1961159Time Stamp: Mar 31, 2024
Lifenet and Eisai Co-Develop Dementia Insurance “be” Source Cluster: JCN Newswire Source Node: 1957889Time Stamp: Mar 21, 2024
This Gene Increases the Risk of Alzheimer’s. Scientists Finally Know Why Source Cluster: Singularity Hub Source Node: 1956508Time Stamp: Mar 15, 2024
Eisai Invests in C2N to Support Simplifying the Diagnosis of Early Alzheimer’s Disease to Better Serve Patients Source Cluster: JCN Newswire Source Node: 1954073Time Stamp: Mar 6, 2024
Focused ultrasound plus plaque-reducing drugs could slow Alzheimer’s progression – Physics World Source Cluster: Physics World Source Node: 1940401Time Stamp: Jan 24, 2024